Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Breast Cancer | Interactive Tumor Panel: Clinical Investigators Discuss Emerging Research and Actual Cases of Patients with Breast Cancer

2:32:18
 
Share
 

Manage episode 237059285 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina:

  • Introduction
    • Program overview: Dr Love (00:00)
  • Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC)
    • Case (Dr Rugo): A woman in her mid-40s with ER/PR-negative, HER2-positive BC who received neoadjuvant TCHP and experienced a pathologic complete response (3:57)
    • Case (Dr Rugo): A woman in her mid-50s with an ER-positive, HER2-positive infiltrating lobular carcinoma who received neoadjuvant chemotherapy/anti-HER2 therapy, had residual disease at surgery and initiated treatment with T-DM1 (6:39)
    • Case (Dr Rugo): A woman in her early 40s with an ER-positive, HER2-positive IDC who received postadjuvant neratinib (11:42)
    • Faculty Presentation: Dr Rugo (14:18)
  • Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC
    • Case (Dr Kaklamani): A postmenopausal woman in her late 50s with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 24 (38:46)
    • Case (Dr Kaklamani): A postmenopausal woman in her mid-50s with an ER/PR-positive, HER2-negative IDC with 2 positive nodes and a 21-gene Recurrence Score of 21 (41:47)
    • Faculty Presentation: Dr Kaklamani (48:39)
  • Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease
    • Case (Prof André): A postmenopausal woman in her mid-50s who presented with ER/PR-positive, HER2-negative mBC approximately 2 years after the completion of adjuvant letrozole (1:07:13)
    • Case (Prof André): A woman in her mid-70s with de novo ER/PR-positive, HER2-negative mBC with extensive liver involvement who received palbociclib/letrozole (1:10:03)
    • Faculty Presentation: Prof André (1:11:05)
  • Immunotherapy as a Rational Therapeutic Strategy in BC
    • Case (Dr Tolaney): A woman in her early 60s with metastatic triple-negative BC (TNBC) who received atezolizumab/nab paclitaxel and remains NED 4 years later (1:28:14)
    • Case (Dr Tolaney): A woman in her mid-60s with heavily pretreated TNBC who experienced a complete response to pembrolizumab but developed treatment-related diabetes and hypothyroidism (1:31:00)
    • Faculty Presentation: Dr Tolaney (1:32:49)
  • Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC
    • Case (Dr Pegram): A woman in her mid-60s with widespread ER-negative, HER2-positive mBC who received tucatinib/capecitabine/trastuzumab on a clinical trial (1:46:01)
    • Faculty Presentation: Dr Pegram (1:47:28)
  • Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer
    • Case (Dr Traina): A woman in her early 60s with metastatic TNBC and a germline BRCA2 mutation who received olaparib monotherapy and achieved a complete response (2:11:31)
    • Case (Dr Traina): A woman in her early 70s with metastatic androgen receptor-positive TNBC who received an investigational antiandrogen on a clinical trial (2:13:12)
    • Case (Dr Traina): A man in his early 60s with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation (2:16:16)
    • Faculty Presentation: Dr Traina (2:18:32)

Select publications

  continue reading

1296 episodes

Artwork
iconShare
 
Manage episode 237059285 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina:

  • Introduction
    • Program overview: Dr Love (00:00)
  • Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC)
    • Case (Dr Rugo): A woman in her mid-40s with ER/PR-negative, HER2-positive BC who received neoadjuvant TCHP and experienced a pathologic complete response (3:57)
    • Case (Dr Rugo): A woman in her mid-50s with an ER-positive, HER2-positive infiltrating lobular carcinoma who received neoadjuvant chemotherapy/anti-HER2 therapy, had residual disease at surgery and initiated treatment with T-DM1 (6:39)
    • Case (Dr Rugo): A woman in her early 40s with an ER-positive, HER2-positive IDC who received postadjuvant neratinib (11:42)
    • Faculty Presentation: Dr Rugo (14:18)
  • Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC
    • Case (Dr Kaklamani): A postmenopausal woman in her late 50s with an ER/PR-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 24 (38:46)
    • Case (Dr Kaklamani): A postmenopausal woman in her mid-50s with an ER/PR-positive, HER2-negative IDC with 2 positive nodes and a 21-gene Recurrence Score of 21 (41:47)
    • Faculty Presentation: Dr Kaklamani (48:39)
  • Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease
    • Case (Prof André): A postmenopausal woman in her mid-50s who presented with ER/PR-positive, HER2-negative mBC approximately 2 years after the completion of adjuvant letrozole (1:07:13)
    • Case (Prof André): A woman in her mid-70s with de novo ER/PR-positive, HER2-negative mBC with extensive liver involvement who received palbociclib/letrozole (1:10:03)
    • Faculty Presentation: Prof André (1:11:05)
  • Immunotherapy as a Rational Therapeutic Strategy in BC
    • Case (Dr Tolaney): A woman in her early 60s with metastatic triple-negative BC (TNBC) who received atezolizumab/nab paclitaxel and remains NED 4 years later (1:28:14)
    • Case (Dr Tolaney): A woman in her mid-60s with heavily pretreated TNBC who experienced a complete response to pembrolizumab but developed treatment-related diabetes and hypothyroidism (1:31:00)
    • Faculty Presentation: Dr Tolaney (1:32:49)
  • Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC
    • Case (Dr Pegram): A woman in her mid-60s with widespread ER-negative, HER2-positive mBC who received tucatinib/capecitabine/trastuzumab on a clinical trial (1:46:01)
    • Faculty Presentation: Dr Pegram (1:47:28)
  • Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer
    • Case (Dr Traina): A woman in her early 60s with metastatic TNBC and a germline BRCA2 mutation who received olaparib monotherapy and achieved a complete response (2:11:31)
    • Case (Dr Traina): A woman in her early 70s with metastatic androgen receptor-positive TNBC who received an investigational antiandrogen on a clinical trial (2:13:12)
    • Case (Dr Traina): A man in his early 60s with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation (2:16:16)
    • Faculty Presentation: Dr Traina (2:18:32)

Select publications

  continue reading

1296 episodes

所有剧集

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide